Eicosatetraynoic Acid Regulates Profibrotic Pathways in an Induced Pluripotent Stem Cell-Derived Macrophage-Human Intestinal Organoid Model of Crohn's Disease
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2025 · 1 min read
In brief
In brief
Researchers developed a novel iPSC-derived macrophage-intestinal organoid model to study Crohn's disease stricture formation and test eicosatetraynoic acid (ETYA) as a potential antifibrotic therapy. ETYA suppressed profibrotic pathways in LPS-stimulated macrophages and reduced collagen deposition in organoid cocultures, suggesting a therapeutic strategy for preventing strictures in refractory CD.
Written by the GCMD Library team from the article.
Statements in this article
Induced pluripotent stem cell-derived macrophages exhibited morphology similar to primary macrophages and expressed inflammatory macrophage cell surface markers including CD64 and CD68.
Lipopolysaccharide-stimulated macrophages expressed a global pattern of gene expression enriched in Crohn's disease ileal inflammatory macrophages and matrisome-secreted products.
Lipopolysaccharide-stimulated macrophages produced cytokines and chemokines including CCL2, IL1B, and OSM implicated in refractory disease.
Eicosatetraynoic acid suppressed CD64 abundance and profibrotic gene expression pathways in lipopolysaccharide-stimulated macrophages.
